Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Beacock-Sharp, H.
Right arrow Articles by Mowat, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beacock-Sharp, H.
Right arrow Articles by Mowat, A. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 15, No. 6, pp. 711-720, June 2003
© 2003 Japanese Society for Immunology

A role for dendritic cells in the priming of antigen-specific CD4+ and CD8+ T lymphocytes by immune-stimulating complexes in vivo

Helen Beacock-Sharp1, Anne M. Donachie1, Neil C. Robson1 and Allan M. Mowat1

1 Department of Immunology and Bacteriology, University of Glasgow, Western Infirmary, Glasgow G11 6NT, UK

Correspondence to: A. M. Mowat; E-mail: a.m.mowat{at}clinmed.gla.ac.uk
Transmitting editor: A. Cooke

Immune-stimulating complexes (ISCOMS) are adjuvant vectors which are unusual in being able to prime both CD4+ and CD8+ T cells by parenteral and mucosal routes. However, their mode of action is unclear and to define better the cellular interactions involved we have studied the ability of ISCOMS containing ovalbumin (OVA) to prime TCR transgenic CD4+ or CD8+ T cells in vivo. Immunization with OVA ISCOMS caused activation and clonal expansion of CD4+ and CD8+ T cells in the T cell areas of the draining lymph nodes, followed by the migration of both CD4+ and CD8+ T cells into the B cell follicle. The T cells were primed to proliferate and secrete IFN-{gamma} after re-stimulation in vitro with the appropriate OVA peptide and CD8+ T cell priming occurred in the absence of CD4+ T cells. Increasing the number of dendritic cells (DC) in vivo with flt3 ligand augmented the expansion and activation of the OVA-specific T cells, particularly CD8+ T cells. These studies indicate DC play a central role in the priming of both CD4+ and CD8+ T cells in vivo, and suggest that an ability to target DC may allow ISCOMS to be powerful vaccine vectors for stimulating protective immunity.

Keywords: adoptive transfer, CD4+ T cell, CD8+ T cell


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
A. Helgeby, N. C. Robson, A. M. Donachie, H. Beackock-Sharp, K. Lovgren, K. Schon, A. Mowat, and N. Y. Lycke
The Combined CTA1-DD/ISCOM Adjuvant Vector Promotes Priming of Mucosal and Systemic Immunity to Incorporated Antigens by Specific Targeting of B Cells
J. Immunol., March 15, 2006; 176(6): 3697 - 3706.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Maraskovsky, S. Sjolander, D. P. Drane, M. Schnurr, T. T. T. Le, L. Mateo, T. Luft, K.-A. Masterman, T.-Y. Tai, Q. Chen, et al.
NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors
Clin. Cancer Res., April 15, 2004; 10(8): 2879 - 2890.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.